Tumour Necrosis Factor-a and tuberculosis: Guidance from the National TB Advisory Committee

Irish Medical Journal

Volumn 101, Issue 1, 2008, Pages

  Kavanagh, Paul M ^a   Glimartin, J J ^b   O'Donnell, J ^a   O'Flanagan, D ^a  

^a HEALTH PROTECTION SURVEILLANCE CENTRE   (Ireland)

^b Merlin Park University Hospital   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; ISONIAZID; PYRIDOXINE; RIFAMPICIN; TUBERCULOSTATIC AGENT; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; ANTIINFLAMMATORY AGENT; ANTIRHEUMATIC AGENT; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR;

ADVISORY COMMITTEE; ANKYLOSING SPONDYLITIS; ARTICLE; COMORBIDITY; DIAGNOSTIC VALUE; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG USE; ENTERITIS; EVIDENCE BASED MEDICINE; GOOD CLINICAL PRACTICE; HIGH RISK PATIENT; HUMAN; IMMUNE DEFICIENCY; IMMUNOPATHOLOGY; INCIDENCE; INFECTION RISK; IRELAND; NONHUMAN; PRACTICE GUIDELINE; PSORIASIS; PSORIATIC ARTHRITIS; REFERENCE VALUE; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; RISK MANAGEMENT; RISK REDUCTION; TREATMENT DURATION; TUBERCULIN TEST; TUBERCULOSIS; ANTIBIOTIC PROPHYLAXIS; DRUG ANTAGONISM; EDITORIAL; PHYSIOLOGY;

ADVISORY COMMITTEES; ANTI-INFLAMMATORY AGENTS; ANTIBIOTIC PROPHYLAXIS; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ANTITUBERCULAR AGENTS; HUMANS; IMMUNE SYSTEM DISEASES; IMMUNOGLOBULIN G; IRELAND; PRACTICE GUIDELINES AS TOPIC; RECEPTORS, TUMOR NECROSIS FACTOR; TUBERCULOSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 42949097025     PISSN: 03323102     EISSN: 03323102     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Keane J, Gershon S, Wise RP, Mirabelle-Levens E, Kaszinca J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumour necrosis a-neutralizing agent. N Engl J Med 2001;345: 1098-104.
2. Gardam MA, Keystone EC, Menzies R, Manners S, Skamene E, Long R, Vinh DC. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 2003; 3:148-55.
3. National TB Advisory Committee. Recommendations for the management of the risk of TB associated with the use of TNF-a antagonists in an Irish setting. http://www.ndsc.ie/hpsc/A-Z/VaccinePreventable/TuberculosisTB/ Guidance/File,2503,en.pdf (last accessed 14th of September 2007).
4. Choy EHS, Panayi GS. Mechanisms of disease: cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001;344:907-916.
5. Van Deventer SJ. Tumour necrosis factor and Crohn's disease. Gut 1997;40:443-448.
6. Ehlers S. Role of tumour necrosis factor (TNF) in host defence against tuberculosis: implications for immunotherapies targeting TNF. Ann Rheum Dis 2003;62 (Suppl II):ii37-ii42.
7. Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD, on behalf of the BIOBADASER Group. Treatment of rheumatoid arthritis with tumour necrosi s factor inhibitors may predispose to significant increase in tuberculosis risk: a multicentre active - surveillance report. Arthritis Rheum 2003;48:2122-2127.
8. Wolfe F, Michaub K, Anderson J, Urbansky K. Tuberculosis infection in patients with rheumatoid arthritis and the effect of Infliximab therapy. Arthritis Rheum 2004;50:372-379.
9. Mohan AK, Cote TR, Block JA, Manadan AM, Siegel IN, Braun MM. Tuberculosis following the use of Etanercept, a tumour necrosis factor inhibitor. Clin Infect Dis 2004;39:295-9.
10. CDC. Tuberculosis associated with blocking agents against tumour necrosis factors-alpha California, 2002-2003. MMWR Morb Mortal Wkly Rep 2004;53:683-686.
11. Wagner TE, Huseby ES, Huseby JS. Excerbation of Mycobacterium Tuberculosis Enteritis masquerading as Crohn's Disease after treatment with a tumour necrosis-a inhibitor. Am J Med 2002;112: 67-9.
12. Mariette X, Salmon D, GROUP RATIO. French guidelines for the diagnosis and treating latent and active tuberculosis in patients with RA treated with TNF blockers. Ann Rheum Dis 2003;62:791.
13. British Thoracic Society Standards of Care Committee. BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-a treatment. Thorax 2005;60:800-805.
14. Carmona L, Gomez-Reino JJ, Valverde VR, Montero MD, Pascual- Gomez E, Mola EM, et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients with tumour necrosis factor antagonists. Arthritis Rheum 2005;52:1766-1772.